1.66
0.05 (3.11%)
| Previous Close | 1.61 |
| Open | 1.64 |
| Volume | 4,348,396 |
| Avg. Volume (3M) | 4,229,693 |
| Market Cap | 1,238,904,832 |
| Price / Sales | 2.25 |
| Price / Book | 1.07 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2026 |
| Profit Margin | -5.66% |
| Operating Margin (TTM) | -44.79% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | -13.70% |
| Total Debt/Equity (MRQ) | 37.58% |
| Current Ratio (MRQ) | 2.49 |
| Operating Cash Flow (TTM) | -182.48 M |
| Levered Free Cash Flow (TTM) | -107.74 M |
| Return on Assets (TTM) | -8.20% |
| Return on Equity (TTM) | -3.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Opko Health, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.33 |
Select this tab to load the latest available analysis.
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 46.81% |
| % Held by Institutions | 30.94% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |